Therapy for the Brugada syndrome.
1Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY 13501, USA. ca@mmrl.edu
Handbook of Experimental Pharmacology
|April 14, 2006
Summary
Brugada syndrome, a genetic disorder, causes sudden cardiac death in young adults. Treatment involves implantable cardioverter-defibrillators (ICDs) or medications to manage electrical activity and prevent fatal arrhythmias.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Brugada syndrome is a congenital disorder linked to sudden cardiac death.
- It presents with characteristic ECG changes (coved ST elevation) in right precordial leads.
- The syndrome poses a high risk for sudden cardiac death in young adults, infants, and children.
Purpose of the Study:
- To review the characteristics, triggers, and management of Brugada syndrome.
- To discuss the role of electrocardiography (ECG) in diagnosis and monitoring.
- To explore therapeutic strategies, including device-based and pharmacological interventions.
Main Methods:
- Review of existing literature on Brugada syndrome.
- Analysis of ECG findings and their dynamic nature.
- Discussion of various precipitating factors and their impact.
- Evaluation of current treatment modalities.
Main Results:
- ECG manifestations can be dynamic and unmasked by specific agents or conditions.
- Triggers include fever, certain medications, and substance toxicity.
- Implantable cardioverter-defibrillators (ICDs) are the primary therapy.
- Pharmacological approaches aim to balance ion channel currents to prevent ventricular arrhythmias.
Conclusions:
- Brugada syndrome requires careful diagnosis and risk stratification.
- Management strategies focus on preventing sudden cardiac death through ICDs or targeted pharmacological therapy.
- Further research into pharmacological agents like isoproterenol, cilostazol, and quinidine is ongoing.
More Related Videos
09:20Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...